Győrffy B - Search Results

1

The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.

Sánchez-Tilló E, Fanlo L, Siles L, Montes-Moreno S, Moros A, Chiva-Blanch G, Estruch R, Martinez A, Colomer D, Győrffy B, Roué G, Postigo A. Sánchez-Tilló E, et al. Among authors: gyorffy b. Cell Death Differ. 2014 Feb;21(2):247-57. doi: 10.1038/cdd.2013.123. Epub 2013 Sep 6. Cell Death Differ. 2014. PMID: 24013721 Free PMC article.

2

ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1.

de Barrios O, Győrffy B, Fernández-Aceñero MJ, Sánchez-Tilló E, Sánchez-Moral L, Siles L, Esteve-Arenys A, Roué G, Casal JI, Darling DS, Castells A, Postigo A. de Barrios O, et al. Among authors: gyorffy b. Gut. 2017 Apr;66(4):666-682. doi: 10.1136/gutjnl-2015-310838. Epub 2016 Dec 13. Gut. 2017. PMID: 27965283

3

Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles.

Cortés M, Sanchez-Moral L, de Barrios O, Fernández-Aceñero MJ, Martínez-Campanario MC, Esteve-Codina A, Darling DS, Győrffy B, Lawrence T, Dean DC, Postigo A. Cortés M, et al. Among authors: gyorffy b. EMBO J. 2017 Nov 15;36(22):3336-3355. doi: 10.15252/embj.201797345. Epub 2017 Oct 16. EMBO J. 2017. PMID: 29038174 Free PMC article.

4

Resistance-associated signatures in breast cancer.

Györffy B. Györffy B. Recent Results Cancer Res. 2007;176:37-50. doi: 10.1007/978-3-540-46091-6_5. Recent Results Cancer Res. 2007. PMID: 17607915

5

Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.

Pénzváltó Z, Tegze B, Szász AM, Sztupinszki Z, Likó I, Szendrői A, Schäfer R, Győrffy B. Pénzváltó Z, et al. Among authors: gyorffy b. PLoS One. 2013;8(3):e59503. doi: 10.1371/journal.pone.0059503. Epub 2013 Mar 29. PLoS One. 2013. PMID: 23555683 Free PMC article.

6

Biomarkers for systemic therapy in ovarian cancer.

Penzvalto Z, Surowiak P, Gyorffy B. Penzvalto Z, et al. Among authors: gyorffy b. Curr Cancer Drug Targets. 2014;14(3):259-73. doi: 10.2174/1568009614666140310120107. Curr Cancer Drug Targets. 2014. PMID: 24605893

7

HIF-3α1 promotes colorectal tumor cell growth by activation of JAK-STAT3 signaling.

Xue X, Jungles K, Onder G, Samhoun J, Győrffy B, Hardiman KM. Xue X, et al. Among authors: gyorffy b. Oncotarget. 2016 Mar 8;7(10):11567-79. doi: 10.18632/oncotarget.7272. Oncotarget. 2016. PMID: 26871465 Free PMC article.

8

Comparative promoter analysis of doxorubicin resistance-associated genes suggests E47 as a key regulatory element.

Gyorffy A, Vásárhelyi B, Szöke D, Dietel M, Tulassay T, Györffy B. Gyorffy A, et al. Among authors: gyorffy b. Anticancer Res. 2006 Jul-Aug;26(4B):2971-6. Anticancer Res. 2006. PMID: 16886622 Free article.

9

Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer.

Szöke D, Györffy A, Surowiak P, Tulassay Z, Dietel M, Györffy B. Szöke D, et al. Among authors: gyorffy a, gyorffy b. Onkologie. 2007 Sep;30(8-9):421-6. doi: 10.1159/000104490. Epub 2007 Sep 7. Onkologie. 2007. PMID: 17848813

10

PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.

Munkácsy G, Abdul-Ghani R, Mihály Z, Tegze B, Tchernitsa O, Surowiak P, Schäfer R, Györffy B. Munkácsy G, et al. Among authors: gyorffy b. Br J Cancer. 2010 Jan 19;102(2):361-8. doi: 10.1038/sj.bjc.6605478. Epub 2009 Dec 15. Br J Cancer. 2010. PMID: 20010949 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

457 results

Search Page

Filters